ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia

References

• Wickremasinghe RG, Prentice AG, Steele AJ. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia 2011; 25:1400 - 7; http://dx.doi.org/10.1038/leu.2011.103; PMID: 21566651
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101 - 5; http://dx.doi.org/10.1038/nature10113; PMID: 21642962
   PubMed Web of Science ®Google Scholar
• Mansouri L, Cahill N, Gunnarsson R, Smedby KE, Tjönnfjord E, Hjalgrim H, et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 2013; 27:512 - 4; http://dx.doi.org/10.1038/leu.2012.307; PMID: 23138133
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Mansouri L, Rosenquist R. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies. Leuk Lymphoma 2013; http://dx.doi.org/10.3109/10428194.2012.751530; PMID: 23167608
   PubMed Web of Science ®Google Scholar
• Maffei R, Marasca R, Martinelli S, Castelli I, Santachiara R, Morandi E, et al. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. Leukemia 2007; 21:1312 - 5; http://dx.doi.org/10.1038/sj.leu.2404650; PMID: 17361220
   PubMed Web of Science ®Google Scholar
• Maffei R, Martinelli S, Santachiara R, Rossi D, Guarnotta C, Sozzi E, et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010; 116:584 - 92; http://dx.doi.org/10.1182/blood-2009-11-252494; PMID: 20382847
   PubMed Web of Science ®Google Scholar
• Hüttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A, Nückel H, et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006; 20:1774 - 82; http://dx.doi.org/10.1038/sj.leu.2404363; PMID: 16932341
   PubMed Web of Science ®Google Scholar
• Maffei R, Martinelli S, Castelli I, Santachiara R, Zucchini P, Fontana M, et al. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 2010; 34:312 - 21; http://dx.doi.org/10.1016/j.leukres.2009.06.023; PMID: 19616847
   PubMed Web of Science ®Google Scholar
• Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000; 14:1414 - 8; http://dx.doi.org/10.1038/sj.leu.2401825; PMID: 10942237
   PubMed Web of Science ®Google Scholar
• Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002; 100:3344 - 51; http://dx.doi.org/10.1182/blood-2002-01-0084; PMID: 12384436
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55 - 60; http://dx.doi.org/10.1126/science.277.5322.55; PMID: 9204896
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242 - 8; http://dx.doi.org/10.1038/35025215; PMID: 11001067
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994 - 8; http://dx.doi.org/10.1126/science.284.5422.1994; PMID: 10373119
   PubMed Web of Science ®Google Scholar
• Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in leukemia?. Hematology Am Soc Hematol Educ Program 2011; 2011:1 - 8; http://dx.doi.org/10.1182/asheducation-2011.1.1; PMID: 22160005
   PubMed Web of Science ®Google Scholar
• Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, Vacca A. Hematopoietic cancer and angiogenesis. Stem Cells Dev 2004; 13:484 - 95; http://dx.doi.org/10.1089/scd.2004.13.484; PMID: 15588506
   PubMed Web of Science ®Google Scholar
• Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003; 45:227 - 44; http://dx.doi.org/10.1016/S1040-8428(02)00135-X; PMID: 12633837
   PubMed Web of Science ®Google Scholar
• Plank MJ, Sleeman BD, Jones PF. The role of the angiopoietins in tumour angiogenesis. Growth Factors 2004; 22:1 - 11; http://dx.doi.org/10.1080/08977190310001643218; PMID: 15179939
   PubMed Web of Science ®Google Scholar
• Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007; 33:7 - 15; http://dx.doi.org/10.1016/j.ejso.2006.07.015; PMID: 16962282
   PubMed Web of Science ®Google Scholar
• Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007; 21:1901 - 6; http://dx.doi.org/10.1038/sj.leu.2404820; PMID: 17597808
   PubMed Web of Science ®Google Scholar
• Xia Y, Lu RN, Li J. Angiogenic factors in chronic lymphocytic leukemia. Leuk Res 2012; 36:1211 - 7; http://dx.doi.org/10.1016/j.leukres.2012.05.021; PMID: 22727510
   PubMed Web of Science ®Google Scholar
• Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther 2010; 12:487 - 95; PMID: 20677100
   PubMed Web of Science ®Google Scholar
• Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012; 40:1321 - 30; PMID: 22327175
   PubMed Web of Science ®Google Scholar
• Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, Greene W, et al. Kaposi’s sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007; 81:3980 - 91; http://dx.doi.org/10.1128/JVI.02089-06; PMID: 17287278
   PubMed Web of Science ®Google Scholar
• Niu G, Carter WB. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 2007; 67:1487 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-06-3155; PMID: 17308086
   PubMed Web of Science ®Google Scholar
• Krug S, Huth J, Göke F, Buchholz M, Gress TM, Göke R, et al. Knock-down of Pdcd4 stimulates angiogenesis via up-regulation of angiopoietin-2. Biochim Biophys Acta 2012; 1823:789 - 99; http://dx.doi.org/10.1016/j.bbamcr.2012.01.006; PMID: 22289349
   PubMed Web of Science ®Google Scholar
• Kanduri M, Cahill N, Göransson H, Enström C, Ryan F, Isaksson A, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010; 115:296 - 305; http://dx.doi.org/10.1182/blood-2009-07-232868; PMID: 19897574
   PubMed Web of Science ®Google Scholar
• Cahill N, Bergh AC, Kanduri M, Göransson-Kultima H, Mansouri L, Isaksson A, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013; 27:150 - 8; http://dx.doi.org/10.1038/leu.2012.245; PMID: 22922567
   PubMed Web of Science ®Google Scholar
• Cahill N, Rosenquist R. Uncovering the DNA methylome in chronic lymphocytic leukemia. Epigenetics 2013; 8:138 - 48; http://dx.doi.org/10.4161/epi.23439; PMID: 23321535
   PubMed Web of Science ®Google Scholar
• Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, et al. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med 2009; 7:76; http://dx.doi.org/10.1186/1479-5876-7-76; PMID: 19715592
   PubMed Web of Science ®Google Scholar
• Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. Leuk Lymphoma 2013; http://dx.doi.org/10.3109/10428194.2013.783913; PMID: 23480493
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Miller KC, Marshall P, Padmanabhan S, Brady W, Bernstein ZP, et al. Thalidomide (T) in combination with fludarabine (F) as initial therapy for patients (pts) with treatment naive chronic lymphocytic leukemia (CLL): preliminary results of a phase I/II clinical trial. [abstract 2974] Blood 2005; 106; PMID: 16174759
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Miller KC, DiMiceli L, Padmanabhan S, Lawrence D, Bernstein ZP, et al. Results of phase II study of lenalidomide (L) {Revlimid(R)} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). [abstract 447] Blood 2005; 106; PMID: 16174759
   PubMed Web of Science ®Google Scholar
• Amin S, Walsh M, Wilson C, Parker AE, Oscier D, Willmore E, et al. Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. J Cell Mol Med 2012; 16:2074 - 84; http://dx.doi.org/10.1111/j.1582-4934.2011.01503.x; PMID: 22151263
   PubMed Web of Science ®Google Scholar
• Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005; 23:3877 - 85; http://dx.doi.org/10.1200/JCO.2005.02.196; PMID: 15809452
   PubMed Web of Science ®Google Scholar
• Rahmatpanah FB, Carstens S, Hooshmand SI, Welsh EC, Sjahputera O, Taylor KH, et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 2009; 1:39 - 61; http://dx.doi.org/10.2217/epi.09.10; PMID: 20495622
   PubMed Web of Science ®Google Scholar
• De Smet C, Loriot A. DNA hypomethylation and activation of germline-specific genes in cancer. Adv Exp Med Biol 2013; 754:149 - 66; http://dx.doi.org/10.1007/978-1-4419-9967-2_7; PMID: 22956500
   PubMed Web of Science ®Google Scholar
• Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A 2012; 109:2555 - 60; http://dx.doi.org/10.1073/pnas.1200003109; PMID: 22308499
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al, International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446 - 56; http://dx.doi.org/10.1182/blood-2007-06-093906; PMID: 18216293
   PubMed Web of Science ®Google Scholar
• Marasca R, Maffei R, Morselli M, Zucchini P, Castelli I, Martinelli S, et al. Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia. J Mol Diagn 2005; 7:566 - 74; http://dx.doi.org/10.1016/S1525-1578(10)60589-2; PMID: 16258154
   PubMed Web of Science ®Google Scholar
• Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007; 21:697 - 705; PMID: 17301820
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848 - 54; PMID: 10477713
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98:2633 - 9; http://dx.doi.org/10.1182/blood.V98.9.2633; PMID: 11675331
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Marini R, et al. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica 2004; 89:1468 - 75; PMID: 15590397
   PubMed Web of Science ®Google Scholar
• Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999; 23:127 - 36; http://dx.doi.org/10.1016/S0145-2126(98)00154-4; PMID: 10071128
   PubMed Web of Science ®Google Scholar
• Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 1975; 5:319 - 34; PMID: 181343
   PubMed Web of Science ®Google Scholar
• Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283 - 98; http://dx.doi.org/10.1016/S0001-2998(78)80014-2; PMID: 112681
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32 - 5; http://dx.doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; PMID: 15405679
   PubMed Web of Science ®Google Scholar